Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 2/20 | 0.61 |
| ▸ | TGM2 | P21980 | 10/20 | 0.48 |
| ▸ | GALR3 | O60755 | 2/20 | 0.47 |
| ▸ | PBRM1 | Q86U86 | 4/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9835981 | 1.00 | CES1 (0.61) | CES1TGM2GALR3PBRM1IDO1 | |
| SCHEMBL5741222 | 0.81 | POLB (0.51) | CES1PBRM1IDO1 | |
| SCHEMBL5752424 | 0.79 | CES1 (0.61) | CES1TGM2GALR3IDO1 | |
| SCHEMBL282066 | 0.76 | CES1 (1.00) | CES1TGM2PBRM1 | |
| SCHEMBL30716604 | 0.76 | CES1 (1.00) | CES1TGM2PBRM1 | |
| SCHEMBL5740135 | 0.75 | CES1 (0.58) | CES1TGM2 | |
| Nitrogen SCHEMBL29242307 | 0.73 | CES1 (0.92) | CES1TGM2PBRM1 | |
| SCHEMBL11530748 | 0.72 | CES1 (0.61) | CES1TGM2GALR3IDO1 | |
| SCHEMBL5988948 | 0.72 | CES1 (0.61) | CES1TGM2GALR3IDO1 | |
| SCHEMBL5989290 | 0.72 | LRRK2 (0.50) | GALR3IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644362-A2 | INDOLINONE HYDRAZIDES AS C-MET INHIBITORS | Sugen, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20060009493-A1 | Indolinone hydrazides as c-Met inhibitors | SUGEN, INC. | 2006-01-12 | — | — | US | disclosed |
| WO-2005005378-A2 | INDOLINONE HYDRAZIDES AS C-MET INHIBITORS | SUGEN, INC. (US) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009493-A1 | Indolinone hydrazides as c-Met inhibitors | MET, IGF1R, ROS1 | CES1 1061/4885TGM2 2673/4885GALR3 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.